<DOC>
	<DOCNO>NCT01266564</DOCNO>
	<brief_summary>This observational study assess progression-free survival , overall response safety Avastin ( bevacizumab ) combination chemotherapy real life set patient metastatic colorectal cancer . Data collect patient approximately 2 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , age &gt; /=18 year Proven metastatic colorectal carcinoma Patients measurable disease Patients eligible receive firstline Avastin Patients sign data release form Contraindication receive Avastin accord local labeling Participation clinical study within 30 day prior enrolment Patients primary cancer Concomitant treatment biologics History malignant disease past 5 year except basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>